About the Event
A Blockbuster drug is defined as one that achieves $1B in annual sales or more. So, what do you call a drug with the potential to generate more than $100B in sales?
AyuVis has developed a first-in-class small molecule immunotherapy that prevents and treats a range of acute and chronic diseases. This single compound is an anti-inflammatory and anti-microbial therapy which modulates the immune system. Because of this, AVR-48 also has the unique ability to treat multiple diseases in multiple organs including lungs, liver, kidneys, blood, eyes, and skin.
Please join our webinar to hear from AyuVis founder and CEO, Dr. Suchi Acharya, who will talk about the approval process for this new drug that has a global market potential to exceed $100B annually.